Clinical Trial Update: Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on safety of oral azacitidine (CC-486) as maintenance therapy after allogeneic stem cell transplantation in AML or MDS; study completed wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Oral azacitidine (azacitidine (oral formulation))

Snippet

Sponsor: Celgene | Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-11-20